Rhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) in a research report report published on Friday morning, Benzinga reports. They currently have a $50.00 target price on the stock. A number of other equities research analysts have also recently issued reports on RYTM. Wells Fargo & […]

Related Keywords

China ,Recursos Ltda ,Jennifer Kayden Lee ,Joseph Shulman ,Rhythm Pharmaceuticals ,Wells Fargo Company ,China Universal Asset Management Co ,Analyst Recommendations For Rhythm Pharmaceuticals ,Needham Company ,Institutional Trading Of Rhythm Pharmaceuticals ,News Ratings For Rhythm Pharmaceuticals Daily ,Goldman Sachs Group ,Insider Activity At Rhythm Pharmaceuticals ,Whittier Trust Co ,Morgan Stanley ,Nisa Investment Advisors ,Rhythm Pharmaceuticals Company Profile ,Vanguard Group Inc ,Rhythm Pharmaceuticals Stock Performance ,Rhythm Pharmaceuticals Inc ,Free Report ,Get Free Report ,Kayden Lee ,Investment Advisors ,Universal Asset Management ,Gestao De Recursos ,Vanguard Group ,Rhythm Pharmaceuticals Daily ,Nasdaq Rytm ,Rytm ,Medical ,Reiterated Rating ,Needham Company Llc ,